This review evaluated a herbal medication for symptoms of upper respiratory tract infection. The authors concluded that Andrographis paniculata may be an effective treatment with few adverse effects and that further research is justified. The conclusions are in line with the evidence presented and appear appropriately cautious.
Authors' objectives
To assess the efficacy and safety of Andrographis paniculata (A. paniculata) in the treatment of upper respiratory tract infection (URTI).
Searching
MEDLINE, EMBASE, CINAHL, AMED, the Cochrane Library and the British Library's Index of Conference Proceedings were searched, all from inception to June 2003. The search terms were reported and no language restrictions were imposed. The authors also searched the reference lists of retrieved papers and departmental files. Manufacturers and distributors of A. paniculata products were contacted for relevant published or unpublished material. Data on adverse event reports were requested from the World Health Organization (WHO) and the drug safety bodies of the UK, Australia and Germany.
Study selection
Study designs of evaluations included in the review Double-blind controlled trials were eligible for inclusion in the efficacy review; two of the included studies were not randomised. All types of study design were eligible for inclusion in the safety review.
Specific interventions included in the review
Studies of single or combined preparations of oral A. paniculata were eligible for inclusion. The studies included in the efficacy review used standardised extracts of A. paniculata alone or in combination with Eleutherococcus senticosus, except for one study that used a crude drug preparation. The comparator interventions for efficacy studies were placebo or paracetamol. The daily dose of andrographolide ranged from 48 to 360 mg/day in the efficacy review and from 11 mg/day to 10 mg/kg per day for studies included in the safety review.
Participants included in the review
Studies of patients with uncomplicated URTI were eligible for inclusion in the efficacy review. There were no restrictions on participants for the review of safety, and participants in the included studies were healthy volunteers, human immunodeficiency virus (HIV)-positive people, patients with renal stones and patients with cardiac and cerebrovascular disease, as well as those with URTI.
Outcomes assessed in the review
No inclusion criteria for the outcomes were specified. The outcomes assessed in the efficacy review were symptoms and days of sick leave. The outcomes in the safety review were all adverse events experienced.
